The rationale for Low-Molecular Weight Heparin (LMWH) use in SARS-CoV-2 infection
Identifieur interne : 001420 ( Main/Corpus ); précédent : 001419; suivant : 001421The rationale for Low-Molecular Weight Heparin (LMWH) use in SARS-CoV-2 infection
Auteurs : Giovanni Di PerriSource :
- Le infezioni in medicina [ 1124-9390 ] ; 2020.
English descriptors
- KwdEn :
- Adenosine Monophosphate (analogs & derivatives), Adenosine Monophosphate (therapeutic use), Alanine (analogs & derivatives), Alanine (therapeutic use), Anticoagulants (administration & dosage), Anticoagulants (therapeutic use), Antiviral Agents (administration & dosage), Antiviral Agents (therapeutic use), Biomarkers (MeSH), COVID-19 (MeSH), Coronavirus Infections (blood), Coronavirus Infections (complications), Coronavirus Infections (drug therapy), Coronavirus Infections (physiopathology), Critical Care (methods), Disease Management (MeSH), Double-Blind Method (MeSH), Drug Combinations (MeSH), Drug Therapy, Combination (MeSH), Embolism (epidemiology), Embolism (prevention & control), Endothelium, Vascular (physiopathology), Heparin, Low-Molecular-Weight (administration & dosage), Heparin, Low-Molecular-Weight (therapeutic use), Humans (MeSH), Hydroxychloroquine (therapeutic use), Interferon beta-1b (therapeutic use), Lopinavir (therapeutic use), Macrophage Activation (MeSH), Pandemics (MeSH), Pneumonia, Viral (blood), Pneumonia, Viral (complications), Pneumonia, Viral (drug therapy), Pneumonia, Viral (physiopathology), Pulmonary Fibrosis (etiology), Pulmonary Fibrosis (prevention & control), Randomized Controlled Trials as Topic (MeSH), Ritonavir (therapeutic use), Thromboembolism (epidemiology), Thromboembolism (prevention & control), Thrombophilia (blood), Thrombophilia (drug therapy), Thrombophilia (etiology), Thrombosis (epidemiology), Thrombosis (prevention & control).
- MESH :
- chemical , administration & dosage : Anticoagulants, Antiviral Agents, Heparin, Low-Molecular-Weight.
- chemical , analogs & derivatives : Adenosine Monophosphate, Alanine.
- chemical , therapeutic use : Adenosine Monophosphate, Alanine, Anticoagulants, Antiviral Agents, Heparin, Low-Molecular-Weight, Hydroxychloroquine, Interferon beta-1b, Lopinavir, Ritonavir.
- chemical : Biomarkers, Drug Combinations.
- blood : Coronavirus Infections, Pneumonia, Viral, Thrombophilia.
- complications : Coronavirus Infections, Pneumonia, Viral.
- drug therapy : Coronavirus Infections, Pneumonia, Viral, Thrombophilia.
- epidemiology : Embolism, Thromboembolism, Thrombosis.
- etiology : Pulmonary Fibrosis, Thrombophilia.
- methods : Critical Care.
- physiopathology : Coronavirus Infections, Endothelium, Vascular, Pneumonia, Viral.
- prevention & control : Embolism, Pulmonary Fibrosis, Thromboembolism, Thrombosis.
- COVID-19, Disease Management, Double-Blind Method, Drug Therapy, Combination, Humans, Macrophage Activation, Pandemics, Randomized Controlled Trials as Topic.
Abstract
In spite of many ongoing attempts to repurpose existing antivirals, no drugs have emerged yet with the desirable activity against SARS-CoV-2. Hydroxychloroquine, lopinavir/ritonavir, remdesivir, umifenovir, favipiravir, ribavirin and beta-interferon-1 gave rise to variable but still inconsistent proof of clinical efficacy in the treatment of COVID-19. Pathogenetic studies have shown significant differences between commonly defined viral pneumonia and COVID-19 pulmonary disease. In severe forms, immune/inflammatory alterations reminiscent of disease forms like Macrophage Activation Syndrome (MAS) have been described, and therapeutic options other than anti-infective have been proposed and implemented, such as anti-inflammatory and anticoagulative agents. The thrombotic phenomena described in the pulmonary vascular bed of patients with severe COVID-19 suggest the administration of low-molecular weight heparin (LMWH) as standard measure in hospitalized patients with COVID-19.
PubMed: 32532939
Links to Exploration step
pubmed:32532939Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The rationale for Low-Molecular Weight Heparin (LMWH) use in SARS-CoV-2 infection</title><author><name sortKey="Di Perri, Giovanni" sort="Di Perri, Giovanni" uniqKey="Di Perri G" first="Giovanni" last="Di Perri">Giovanni Di Perri</name><affiliation><nlm:affiliation>Clinica di Malattie Infettive, Università degli Studi di Torino, Torino, Italy.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32532939</idno><idno type="pmid">32532939</idno><idno type="wicri:Area/Main/Corpus">001420</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001420</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The rationale for Low-Molecular Weight Heparin (LMWH) use in SARS-CoV-2 infection</title><author><name sortKey="Di Perri, Giovanni" sort="Di Perri, Giovanni" uniqKey="Di Perri G" first="Giovanni" last="Di Perri">Giovanni Di Perri</name><affiliation><nlm:affiliation>Clinica di Malattie Infettive, Università degli Studi di Torino, Torino, Italy.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Le infezioni in medicina</title><idno type="ISSN">1124-9390</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenosine Monophosphate (analogs & derivatives)</term><term>Adenosine Monophosphate (therapeutic use)</term><term>Alanine (analogs & derivatives)</term><term>Alanine (therapeutic use)</term><term>Anticoagulants (administration & dosage)</term><term>Anticoagulants (therapeutic use)</term><term>Antiviral Agents (administration & dosage)</term><term>Antiviral Agents (therapeutic use)</term><term>Biomarkers (MeSH)</term><term>COVID-19 (MeSH)</term><term>Coronavirus Infections (blood)</term><term>Coronavirus Infections (complications)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (physiopathology)</term><term>Critical Care (methods)</term><term>Disease Management (MeSH)</term><term>Double-Blind Method (MeSH)</term><term>Drug Combinations (MeSH)</term><term>Drug Therapy, Combination (MeSH)</term><term>Embolism (epidemiology)</term><term>Embolism (prevention & control)</term><term>Endothelium, Vascular (physiopathology)</term><term>Heparin, Low-Molecular-Weight (administration & dosage)</term><term>Heparin, Low-Molecular-Weight (therapeutic use)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Interferon beta-1b (therapeutic use)</term><term>Lopinavir (therapeutic use)</term><term>Macrophage Activation (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (blood)</term><term>Pneumonia, Viral (complications)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (physiopathology)</term><term>Pulmonary Fibrosis (etiology)</term><term>Pulmonary Fibrosis (prevention & control)</term><term>Randomized Controlled Trials as Topic (MeSH)</term><term>Ritonavir (therapeutic use)</term><term>Thromboembolism (epidemiology)</term><term>Thromboembolism (prevention & control)</term><term>Thrombophilia (blood)</term><term>Thrombophilia (drug therapy)</term><term>Thrombophilia (etiology)</term><term>Thrombosis (epidemiology)</term><term>Thrombosis (prevention & control)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anticoagulants</term><term>Antiviral Agents</term><term>Heparin, Low-Molecular-Weight</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Adenosine Monophosphate</term><term>Alanine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adenosine Monophosphate</term><term>Alanine</term><term>Anticoagulants</term><term>Antiviral Agents</term><term>Heparin, Low-Molecular-Weight</term><term>Hydroxychloroquine</term><term>Interferon beta-1b</term><term>Lopinavir</term><term>Ritonavir</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Biomarkers</term><term>Drug Combinations</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term><term>Thrombophilia</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term><term>Thrombophilia</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Embolism</term><term>Thromboembolism</term><term>Thrombosis</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Pulmonary Fibrosis</term><term>Thrombophilia</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Critical Care</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Coronavirus Infections</term><term>Endothelium, Vascular</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Embolism</term><term>Pulmonary Fibrosis</term><term>Thromboembolism</term><term>Thrombosis</term></keywords><keywords scheme="MESH" xml:lang="en"><term>COVID-19</term><term>Disease Management</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Macrophage Activation</term><term>Pandemics</term><term>Randomized Controlled Trials as Topic</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In spite of many ongoing attempts to repurpose existing antivirals, no drugs have emerged yet with the desirable activity against SARS-CoV-2. Hydroxychloroquine, lopinavir/ritonavir, remdesivir, umifenovir, favipiravir, ribavirin and beta-interferon-1 gave rise to variable but still inconsistent proof of clinical efficacy in the treatment of COVID-19. Pathogenetic studies have shown significant differences between commonly defined viral pneumonia and COVID-19 pulmonary disease. In severe forms, immune/inflammatory alterations reminiscent of disease forms like Macrophage Activation Syndrome (MAS) have been described, and therapeutic options other than anti-infective have been proposed and implemented, such as anti-inflammatory and anticoagulative agents. The thrombotic phenomena described in the pulmonary vascular bed of patients with severe COVID-19 suggest the administration of low-molecular weight heparin (LMWH) as standard measure in hospitalized patients with COVID-19.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32532939</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>22</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1124-9390</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>suppl 1</Issue><PubDate><Year>2020</Year><Month>06</Month><Day>01</Day></PubDate></JournalIssue><Title>Le infezioni in medicina</Title><ISOAbbreviation>Infez Med</ISOAbbreviation></Journal><ArticleTitle>The rationale for Low-Molecular Weight Heparin (LMWH) use in SARS-CoV-2 infection</ArticleTitle><Pagination><MedlinePgn>52-56</MedlinePgn></Pagination><Abstract><AbstractText>In spite of many ongoing attempts to repurpose existing antivirals, no drugs have emerged yet with the desirable activity against SARS-CoV-2. Hydroxychloroquine, lopinavir/ritonavir, remdesivir, umifenovir, favipiravir, ribavirin and beta-interferon-1 gave rise to variable but still inconsistent proof of clinical efficacy in the treatment of COVID-19. Pathogenetic studies have shown significant differences between commonly defined viral pneumonia and COVID-19 pulmonary disease. In severe forms, immune/inflammatory alterations reminiscent of disease forms like Macrophage Activation Syndrome (MAS) have been described, and therapeutic options other than anti-infective have been proposed and implemented, such as anti-inflammatory and anticoagulative agents. The thrombotic phenomena described in the pulmonary vascular bed of patients with severe COVID-19 suggest the administration of low-molecular weight heparin (LMWH) as standard measure in hospitalized patients with COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Di Perri</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Clinica di Malattie Infettive, Università degli Studi di Torino, Torino, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Infez Med</MedlineTA><NlmUniqueID>9613961</NlmUniqueID><ISSNLinking>1124-9390</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006495">Heparin, Low-Molecular-Weight</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C558899">lopinavir-ritonavir drug combination</NameOfSubstance></Chemical><Chemical><RegistryNumber>145155-23-3</RegistryNumber><NameOfSubstance UI="D000068576">Interferon beta-1b</NameOfSubstance></Chemical><Chemical><RegistryNumber>2494G1JF75</RegistryNumber><NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>3QKI37EEHE</RegistryNumber><NameOfSubstance UI="C000606551">remdesivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>415SHH325A</RegistryNumber><NameOfSubstance UI="D000249">Adenosine Monophosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000249" MajorTopicYN="N">Adenosine Monophosphate</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003422" MajorTopicYN="N">Critical Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019468" MajorTopicYN="N">Disease Management</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004617" MajorTopicYN="N">Embolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004730" MajorTopicYN="N">Endothelium, Vascular</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006495" MajorTopicYN="N">Heparin, Low-Molecular-Weight</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068576" MajorTopicYN="N">Interferon beta-1b</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008262" MajorTopicYN="N">Macrophage Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011658" MajorTopicYN="N">Pulmonary Fibrosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013923" MajorTopicYN="N">Thromboembolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019851" MajorTopicYN="N">Thrombophilia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="N">Thrombosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32532939</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001420 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001420 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32532939
|texte= The rationale for Low-Molecular Weight Heparin (LMWH) use in SARS-CoV-2 infection
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32532939" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |